Martin Shkreli
martin@martinshkreli.com
←
|
ROIV.xlsx
|
Main
Model
Vtama
brepocitinib
IP
A
B
C
1
Main
2
Brand
fka
3
Generic
beprocitinib
4
Indication
SLE, dermatomyositis
5
Economics
PFE
6
Clinical Trials
7
Phase III SLE
8
Enrollment completes August 2022, data 2H23
Martin Shkreli